Chick-fil-A vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (92 vs 82)

Chick-fil-A

LeaderConsumer Food & Beverage

Quick Service Restaurant

Largest US chicken QSR with $22B+ system sales; highest revenue per restaurant in fast food through exceptional service culture and tight franchise operator standards.

AI VisibilityBeta
Overall Score
A82
Category Rank
#2 of 6
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
84
Gemini
86

About

Chick-fil-A is the largest US quick-service chicken restaurant chain, generating over $22 billion in annual system-wide sales from approximately 3,000 locations — more revenue per restaurant than any other US fast food chain, including McDonald's. Founded in 1946 by S. Truett Cathy in Hapeville, Georgia, Chick-fil-A pioneered the chicken sandwich and built a brand synonymous with exceptional customer service, clean restaurants, and a distinctive cultural identity. The company is privately held by the Cathy family.

Full profile

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A92
Category Rank
#61 of 1167
AI Consensus
73%
Trend
down
Per Platform
ChatGPT
86
Perplexity
90
Gemini
92

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

82
Overall Score
92
#2
Category Rank
#61
81
AI Consensus
73
stable
Trend
down
92
ChatGPT
86
84
Perplexity
90
86
Gemini
92
90
Claude
98
88
Grok
93

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.